Nakazawa Pharmaceutical Co., Ltd. (Headquarters: Nankoku City, Kochi Prefecture; Representative Director: Kojiro Nakazawa) and Salus Science Co., Ltd. (Headquarters: Kochi City, Kochi Prefecture; Representative Director: Keisuke Taniuchi), a spin-off venture from Kochi University, are pleased to announce that they have entered into a capital and business alliance with the aim of further advancing pancreatic cancer treatment and improving regional healthcare.
Through this partnership, both parties will further strengthen their industry-academia collaboration framework and fully commit to the challenge of delivering new hope for pancreatic cancer treatment from Kochi to the world.
In conjunction with this announcement, a press conference was held at Kochi University’s Asakura Campus. At the conference, Kochi University President Hiroyuki Uchida and other representatives explained the background of this partnership and outlined future business developments aimed at paving the way for the future of regional healthcare.
Press Conference Overview
Details of the press conference and the content of the presentations by the speakers are as follows.
Date and Time: Tuesday, June 2, 2026, 10:30–11:30
Location: Media Hall, 6th Floor, Media no Mori, Kochi University Asakura Campus
Attendees:
Keisuke Taniuchi, Representative Director, Salus Science Co., Ltd. (Associate Professor, Kochi University)
Kojiro Nakazawa, Representative Director, Nakazawa Ujiya Pharmaceutical Co., Ltd.
Hiroyuki Ukeda, President, Kochi University
Masanori Tanaka, Representative Director, Kochi Industry-Academia Collaboration Capital Co., Ltd.
Background of the Partnership and Future Outlook
By integrating the “academic expertise” of cutting-edge pancreatic cancer research with the “corporate network” of a pharmaceutical distributor deeply rooted in the local community, we will establish a system to rapidly deliver innovative medical technologies to the front lines. We invite you to follow the journey of both companies as they venture into uncharted territory in pancreatic cancer treatment, starting from Kochi.
The presentation materials announced at the press conference and the specific roadmap for the partnership are available on the following page.